Related Experiment Video
Updated: Jul 19, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent
Kenneth W Yip1, Emma Ito, Xinliang Mao
1Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
Abstract:
Despite advances in surgery, radiation, and chemotherapy, novel therapeutics are needed for head and neck cancer treatment. The objective of this current study was to evaluate alexidine dihydrochloride as a novel compound lead for head and neck cancers. Using a tetrazolium-based assay, the dose required to reduce cell viability by 50% (ED50) was found to be approximately 1.8 micromol/L in FaDu (human hypopharyngeal squamous cancer) and approximately 2.6 micromol/L in C666-1 (human undifferentiated nasopharyngeal cancer) cells. In contrast, the ED50 values were much higher in untransformed cells, specifically at approximately 8.8 micromol/L in GM05757 (primary normal human fibroblast), approximately 8.9 micromol/L in HNEpC (primary normal human nasal epithelial), and approximately 19.6 micromol/L in NIH/3T3 (mouse embryonic fibroblast) cells. Alexidine dihydrochloride did not interfere with the activities of cisplatin, 5-fluorouracil, or radiation, and interacted in a less-than-additive manner. DNA content analyses and Hoechst 33342 staining revealed that this compound induced apoptosis. Alexidine dihydrochloride-induced mitochondrial damage was visualized using transmission electron microscopy. Mitochondrial membrane potential (DeltaPsiM) depolarization was detectable after only 3 hours of treatment, and was followed by cytosolic Ca2+ increase along with loss of membrane integrity/cell death. Caspase-2 and caspase-9 activities were detectable at 12 hours, caspase-8 at 24 hours, and caspase-3 at 48 hours. FaDu cell clonogenic survival was reduced to < 5% with 1 micromol/L alexidine dihydrochloride, and, correspondingly, this compound decreased the in vivo tumor-forming potential of FaDu cells. Thus, we have identified alexidine dihydrochloride as the first bisbiguanide compound with anticancer specificity.
Insights
Alexidine dihydrochloride shows anticancer specificity against head and neck cancers, inducing apoptosis and reducing tumor formation. This novel bisbiguanide compound offers a promising therapeutic lead for these challenging malignancies.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Head and neck cancers require novel therapeutic strategies beyond current treatments.
- Alexidine dihydrochloride is investigated as a potential new agent.
Purpose of the Study:
- To evaluate alexidine dihydrochloride's efficacy and specificity in head and neck cancer treatment.
- To elucidate the mechanisms of action for alexidine dihydrochloride.
Main Methods:
- Cell viability assays (ED50 determination) in cancer and normal cells.
- Assays for drug interaction, apoptosis induction (DNA content, Hoechst staining), and mitochondrial damage (TEM, membrane potential).
- Caspase activity assays and in vivo tumor formation studies.
Main Results:
- Alexidine dihydrochloride demonstrated selective toxicity towards head and neck cancer cells (FaDu, C666-1) compared to normal cells.
- The compound induced apoptosis via mitochondrial damage and caspase activation.
- It reduced cancer cell clonogenic survival and in vivo tumor-forming potential without interfering with standard therapies.
Conclusions:
- Alexidine dihydrochloride is the first bisbiguanide compound identified with anticancer specificity for head and neck cancers.
- It represents a promising novel therapeutic lead for head and neck cancer treatment.
Related Concept Videos
Diazonium Group Substitution: –OH and –H
Preparation of 1° Amines: Azide Synthesis
Azide ions act as good nucleophiles and react with unhindered alkyl halides to form alkyl azides. Alkyl azides do not participate in further nucleophilic substitution reactions, thereby eliminating the chances of polyalkylated products. Alkyl azides are reduced by hydride-based reducing agents, like lithium aluminum...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Aryldiazonium Salts to Azo Dyes: Diazo Coupling
Physical Properties of Amines
Diazonium Group Substitution with Halogens and Cyanide: Sandmeyer and Schiemann Reactions